NCEL
NewcelX Ltd.
NASDAQ · Healthcare · Biotechnology · CH
$3.34
−0.30%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+13.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Apr 29, 2026 | Samuel Olivier · director | Purchase | 81,818 | $2.75 |
| Apr 29, 2026 | Samuel Olivier · director | Purchase | 114,545 | $3.02 |
| Apr 29, 2026 | Revel Michel · director, 10 percent owner, officer: CSO and Director | Purchase | 54,545 | $2.75 |
| Apr 29, 2026 | Revel Michel · director, 10 percent owner, officer: CSO and Director | Purchase | 76,363 | $3.02 |
Institutional positioning
13F filings over the trailing two quarters
New 5Increased 1Reduced 0Sold out 2
| Filer | Action | Shares | Filed |
|---|---|---|---|
| HRT FINANCIAL LP | New Position | 11,199 | Aug 14, 2026 |
| JONES FINANCIAL COMPANIES LLLP | New Position | 700 | Aug 14, 2026 |
| UBS GROUP AG | New Position | 684 | May 5, 2026 |
| TOWER RESEARCH CAPITAL LLC (TRC) | New Position | 147 | May 15, 2026 |
| Caitong International Asset Management Co., Ltd | Increased | 9 | Aug 5, 2026 |
| CoreCap Advisors, LLC | Unchanged | 3 | Jul 6, 2026 |
| CORECAP ADVISORS, LLC | Unchanged | 3 | Apr 7, 2026 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | New Position | 1 | May 11, 2026 |
| Tower Research Capital LLC (TRC) | Sold Out | 0 | May 15, 2026 |
| UBS Group AG | Sold Out | 0 | May 5, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Apr 29, 2026